Diurnal rhythms and hemostatic factors in atrial fibrillation: reply  by Lip, Gregory Y.H et al.
have identified the peak levels of von Willebrand factor, which
occur around midday (2), in normal subjects, fibrinogen has a
circadian rhythm with peak levels occurring between 9 and 10 AM
and the nadir occurring about 9 and 10 PM (3,4). The sampling
times chosen by Li-Saw-Hee et al. (1) are thus likely to have
missed the peak and nadir levels of fibrinogen, with a consequent
reduction in the power of the study to detect a diurnal difference.
Second, it is not clear whether there are diurnal variations in
soluble p-selectin and thrombomodulin in healthy subjects. Thus,
studies of soluble P-selectin have been inconclusive, with one study
of 12 subjects reporting a decrease in levels at 12 noon (5) but
another study of nine subjects finding an increase in levels at 8 to
9 AM (6). Furthermore, as far as we are aware, there is no published
data about the existence of diurnal variation in thrombomodulin
levels within normal subjects. As Li-Saw-Hee et al. (1) did not
look for circadian changes in these hemostatic factors in their
control group, therefore it seems somewhat premature to conclude
that there has been a “loss” of diurnal variation of soluble p-selectin
and thrombomodulin in patients with atrial fibrillation.
Finally, conclusions about the effects of atrial fibrillation (AF)
on the diurnal pattern of hemostatic factors may have been
confounded by heterogeneity in the clinical features of the patients
studied. Only 50% of patients in the diurnal study had lone AF,
with the remainder having conditions such as hypertension,
diabetes and atherosclerotic disease, all of which are associated
with changes in hemostatic factors independent of cardiac rhythm
(7,8). Furthermore, 15% of the patients were smokers, which is
recognized to have acute effects on both coagulation (9) and
platelet activation (10,11). Moreover, the mean age of the patients
with AF was 73 years and older age is known to be accompanied
by activation of coagulation (12).
Understanding the potential contribution of changes in coagu-
lation processes, platelet activation and endothelial function to the
risk of thromboembolism in patients with AF is clearly an
important area of research. However, elucidation of the mecha-
nisms underlying such changes and their relationship to thrombo-
embolic risk will require rigorous experimental design and also
separation of the effects of AF per se from the influence of other
known modulators of hemostatic factors.
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REPLY
Diurnal rhythms in certain hemostatic factors may contribute to
the clustering of various cardiovascular events at certain times of
the day. We have been unable to find any diurnal variation in the
hypercoagulable state associated with atrial fibrillation (AF), as
indicated by variations in levels of von Willebrand factor, fibrin-
ogen, soluble P-selectin and thrombomodulin, in patients with
chronic AF, that could contribute to the high risk of stroke and
thromboembolism associated with this arrhythmia (1). We are
grateful to Peverill and Smolich for bringing to our attention a
number of previous publications that they consider as having a
bearing on the interpretation of our data.
Peverill and Smolich cite the study by Porta et al. (2), who
reported differences in levels of von Willebrand factor (defined by
immunoelectrophoresis) taken at 13 time points in nine patients
with diabetes who were treated with insulin twice in a 12-h period.
These data were analyzed by paired t testing: we used the
considerably more stringent Freidman’s repeated-measures two-
way analysis of variance. Furthermore, von Willebrand factor levels
are positively associated with insulin (3,4); consequently, we did
not consider the data from Porta et al. (2) to be entirely comparable
with ours. Peverill and Smolich also cite the reports by Kanabrocki
et al. (5,6), which reported levels of fibrinogen taken at eight time
points in 11 men (mean age 55 years) who were heterogeneous for
cardiovascular disease (and its risk factors), and analyzed these data
with a complex procedure (that is unavailable to us) involving “the
fit of a cosine curve by the method of least squares.” Therefore,
these subjects differ from those in our study of carefully selected
patients with chronic AF.
Peverill and Smolich cite two papers reporting essential physi-
ological changes in a cohort of healthy young men, a group most
different to our patients with AF. For example, Jilma et al. (7)
obtained five blood samples from 12 men (mean age 25 years) and
found a diurnal variation in levels of soluble P-selectin. Similarly,
Kirk et al. (8) took seven blood samples from nine men (mean age
23 years) and also found a variation in levels of soluble P-selectin.
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We were aware of both these papers during our study, but we failed
to refer to them as they represent different patient populations to
our own. However, we agree that, as we did not present data on the
diurnal variation in soluble P-selectin and soluble thrombomodu-
lin in healthy subjects, we were perhaps premature to interpret this
data in terms of “loss” of a pattern in the patients with AF,
although this lack of diurnal variation is in keeping with our
hypothesis of a “constant” hypercoagulable state in AF.
Naturally, there are many confounders to be addressed in studies
of thrombosis and hemostasis, and ours is typical in that athero-
sclerosis and its risk factors were present in some of our patients
with AF. It has previously been shown that the hypercoagulable
state in AF is independent of underlying etiology or associated
heart disease (9), and we would emphasize that the main objective
of our study was to assess the circadian or diurnal variation in the
hypercoagulable state in AF, rather than to reproduce many
previous analyses (including our own) of the effects of heart disease
on hypercoagulability in AF. Indeed, we were unable to find any
difference in our research indices comparing those patients with
lone AF with those whose AF was confounded by other disease
(1). Despite this, our cohort of patients are indeed characteristic of
those presenting to the hospital with AF, and so the data are truly
representative of a “real-life” situation.
Gregory Y.H. Lip, MD, FACC
Haemostasis, Thrombosis and Vascular Biology Unit
University Department of Medicine
City Hospital
Birmingham B18 7QH
United Kingdom
E-mail: G.Y.H.LIP@bham.ac.uk
Andrew D. Blann, PhD, MRCPath
F.L. Li-Saw-Hee, MRCP
PII S0735-1097(00)01165-7
REFERENCES
1. Li-Saw-Hee FL, Blann AD, Lip GYH. A cross-sectional and diurnal
study of thrombogenesis among patients with chronic atrial fibrillation.
J Am Coll Cardiol 2000;35:1926–31.
2. Porta M, Maneschi F, White MC, Kohner EM. Twenty-four-hour
variations of von Willebrand factor and factor VIII-related antigen in
diabetic retinopathy. Metabolism 1981;30:695–9.
3. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinaemia,
hyperglycaemia, and impaired haemostasis. JAMA 2000;283:221–8.
4. Conlan MG, Folsum AR, Finch A, et al. Associations of factor VIII
and von Willebrand factor with age, race, sex, and the risk factors for
atherosclerosis. The Atherosclerosis Risk In Communities (ARIC)
Study. Thromb Haemost 1993;70:380–5.
5. Kanabrocki EL, Sothern RB, Messmore HL, et al. Circadian inter-
relationships among levels of plasma fibrinogen, blood platelets, and
serum interleukin-6. Clin Appl Thromb Haemost 1999;5:37–42.
6. Bremner WF, Sothern RB, Kanabrocki EL, et al. Relation between
circadian patterns in levels of circulating lipoprotein(a), fibrinogen,
platelets and related lipid variables in men. Am Heart J 2000;139:164–
73.
7. Jilma B, Szalay T, Dirnberger E, et al. Effects of endothelin-1 on
circulating adhesion molecules in man. Eur J Clin Invest 1997;27:
850–6.
8. Kirk G, Maple C, McLaren M, Belch JJF. A circadian rhythm may exist
in healthy controls for soluble P selectin and platelet count. Platelets
1995;6:414–5.
9. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet
1995;346:1313–4.
C-Reactive Protein and Electron Beam
Computed Tomography: A Perfect Match?
Redberg et al. (1) are incorrect in concluding that electron beam
computed tomography (EBCT) may not predict future coronary
events because there is no evidence of a positive association
between C-reactive protein and coronary calcium. The presence of
atherosclerosis (EBCT calcium) and inflammation (C-reactive
protein) are both predictors of future events. This study adequately
demonstrated that the two are not dependent upon one another.
Published data from the Cholesterol And Recurrent Events
(CARE) trial demonstrated that many patients with established
coronary disease (myocardial infarction [MI]) had normal or low
C-reactive protein levels (2). The significant finding in the
Cholesterol And Recurrent Events (CARE) study is that coronary
disease plus inflammation (C-reactive protein) predicted future
events. However, it is incorrect to assume that a low C-reactive
protein in the setting of MI is protective. These patients are still at
greatly increased risk over non-MI persons. Lack of association of
C-reactive protein with EBCT does not imply that EBCT, nor
C-reactive protein, will fail to predict cardiac events.
The investigators made a series of small errors with the EBCT
literature that deserve comment. They quote a fluoroscopy study
stating “that individuals with normal EBCT scores may nonethe-
less suffer MI.” EBCT is significantly more sensitive than flouro-
scopy for detection of coronary disease and prediction of future
cardiac events. They also state that calcium score is a weak
predictor of coronary death and infarction. A recent meta-analysis
of EBCT demonstrated there was an increased risk for hard events:
MI or death (summary risk ratio 4.2 using median calcium scores)
(3). When studies evaluate the highest quartile of calcium score as
compared with the lowest quartile, odds ratios (ORs) are on the
order of 10 to 20 (4–6). Thus, EBCT is potentially as robust a
predictor of future cardiac events as C-reactive protein (OR of 4.4
using quartile analysis) (7).
The question answered in the paper is that not every asymp-
tomatic person with atherosclerosis has inflammation, which was
known from the CARE study. Atherosclerosis predicts future
cardiac events, inflammation predicts future events, and the com-
bination more strongly predicts future events (2). The detection of
atherosclerosis (calcium by EBCT) and inflammation (C-reactive
protein) might predict future events robustly, and this is actively
being investigated.
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